Current Status of Staging and Restaging Malignant Pleural Mesothelioma. in Seminars in nuclear medicine / Semin Nucl Med. 2025 Mar;55(2):240-251. doi: 10.1053/j.semnuclmed.2025.01.003. Epub 2025 Feb 10.

2025

Tipo pubblicazione

Journal Article; Review;

Autori/Collaboratori (1)

Lopci E
Nuclear Medicine Unit, IRCCS - Humanitas Research Hospital, Rozzano Milano, Italy. Electronic address: egesta.lopci@cancercenter.humanitas.it.

Abstract

Malignant pleural mesothelioma (MPM) is the most frequent aggressive tumor affecting the pleura, accounting for over 38,000 deaths worldwide. It originates from the mesothelial cells and is mostly associated to asbestos exposure. Depending on the extent of the disease, the management of MPM varies from surgical intervention to a combination of systemic chemotherapy, immunotherapy, and radiation therapy. Major International scientific societies provide continuous updates on proper management of the disease, including recommendations on the optimal imaging algorithms, which are crucial for determining effective treatment options and optimizing clinical outcomes. However, despite the continuous efforts to improve patients' prognosis, median overall survival remains poor, ranging from 8 to 14 months. And even in case of initial response to treatment, local or distant recurrences represent almost a certainty, requiring appropriate imaging for the assessment of tumor sites. The aim of the present article is to illustrate the current status of imaging for staging and restaging of MPM, not forgetting most recent novelties in the diagnostic work-up of the disease.

PMID : 39934006

DOI : 10.1053/j.semnuclmed.2025.01.003

Keywords

Humans; Neoplasm Staging; Mesothelioma, Malignant/diagnostic imaging/pathology/therapy; Mesothelioma/diagnostic imaging/pathology/therapy; Pleural Neoplasms/diagnostic imaging/therapy/pathology; Lung Neoplasms/diagnostic imaging/pathology/therapy;